ZA991220B - Method of treating heart failure. - Google Patents

Method of treating heart failure.

Info

Publication number
ZA991220B
ZA991220B ZA9901220A ZA991220A ZA991220B ZA 991220 B ZA991220 B ZA 991220B ZA 9901220 A ZA9901220 A ZA 9901220A ZA 991220 A ZA991220 A ZA 991220A ZA 991220 B ZA991220 B ZA 991220B
Authority
ZA
South Africa
Prior art keywords
heart failure
treating heart
treating
failure
heart
Prior art date
Application number
ZA9901220A
Other languages
English (en)
Inventor
Yuhpyng Liang Chen
Anthony Andrea Fossa
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA991220B publication Critical patent/ZA991220B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9901220A 1998-02-17 1999-02-16 Method of treating heart failure. ZA991220B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7493498P 1998-02-17 1998-02-17

Publications (1)

Publication Number Publication Date
ZA991220B true ZA991220B (en) 2000-08-16

Family

ID=22122537

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9901220A ZA991220B (en) 1998-02-17 1999-02-16 Method of treating heart failure.

Country Status (28)

Country Link
US (1) US6043260A (fr)
EP (1) EP0951906A1 (fr)
JP (1) JPH11292766A (fr)
KR (1) KR19990072616A (fr)
CN (1) CN1231176A (fr)
AP (1) AP9901464A0 (fr)
AR (1) AR017723A1 (fr)
AU (1) AU1732999A (fr)
BG (1) BG103180A (fr)
BR (1) BR9900653A (fr)
CA (1) CA2262252C (fr)
EA (1) EA199900124A3 (fr)
GT (1) GT199900015A (fr)
HR (1) HRP990054A2 (fr)
HU (1) HUP9900386A3 (fr)
ID (1) ID23218A (fr)
IL (1) IL128531A0 (fr)
IS (1) IS4975A (fr)
MA (1) MA26608A1 (fr)
NO (1) NO990722L (fr)
OA (1) OA10976A (fr)
PA (1) PA8467401A1 (fr)
PE (1) PE20000266A1 (fr)
PL (1) PL331507A1 (fr)
SG (1) SG81261A1 (fr)
TN (1) TNSN99024A1 (fr)
TR (1) TR199900328A2 (fr)
ZA (1) ZA991220B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
CA2382547A1 (fr) * 1999-09-21 2001-03-29 Stephen R. Hanson Procedes et compositions de traitement des pathologies apparentees aux plaquettes
AP2002002583A0 (en) * 2000-01-18 2002-09-30 Pfizer Prod Inc Corticotropin releasing factor antagonists.
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
AU2003215379A1 (en) 2002-02-22 2003-09-09 Pharmacia And Upjohn Company Substituted pyrimidinones and pyrimidinthiones
EP1485384A1 (fr) * 2002-03-13 2004-12-15 Pharmacia & Upjohn Company LLC Derives de pyrazolo(1,5-a)pyridine utilises en tant que modulateurs du neurotransmetteur
WO2003091225A1 (fr) * 2002-04-26 2003-11-06 Pharmacia & Upjohn Company Derives pyraziniques substitues
JP2006506350A (ja) * 2002-09-12 2006-02-23 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換１，４−ピラジン誘導体
AR041470A1 (es) * 2002-10-17 2005-05-18 Upjohn Co Compuestos de pirrolo (1,2 - b) piridazina y sus usos
JP2006514628A (ja) * 2002-11-21 2006-05-11 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｃｒｆ変調剤としてのピラジン化合物
MXPA05011387A (es) * 2003-04-23 2005-12-01 Pharmacia & Upjohn Co Llc Pirimidinonas y pirimidinotionas sustituidas.
MXPA05011993A (es) * 2003-05-07 2006-02-02 Pharmacia & Upjohn Co Llc Compuestos de pirrolo[1,2-b]piridazina.
EP1626965A1 (fr) * 2003-05-09 2006-02-22 Pharmacia & Upjohn Company LLC Pyrazinones a titre d'antagonistes du recepteur de crf1 dans le traitement des troubles du systeme nerveux central
WO2004099148A1 (fr) * 2003-05-09 2004-11-18 Pharmacia & Upjohn Company Llc Derives pyrimidiques substitues
CA2524519A1 (fr) * 2003-05-09 2004-11-18 Pharmacia & Upjohn Company Llc Composes utilises comme antagonistes du recepteur de type 1 de la corticoliberine (crf)
WO2005089639A2 (fr) * 2004-03-16 2005-09-29 Talarico M D Matthew T Procede de deregulation vasculaire
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
EP0795327A1 (fr) * 1996-03-13 1997-09-17 Pfizer Inc. Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique

Also Published As

Publication number Publication date
HU9900386D0 (en) 1999-04-28
TNSN99024A1 (fr) 2005-11-10
TR199900328A2 (xx) 1999-10-21
JPH11292766A (ja) 1999-10-26
PE20000266A1 (es) 2000-04-07
US6043260A (en) 2000-03-28
CA2262252A1 (fr) 1999-08-17
KR19990072616A (ko) 1999-09-27
IL128531A0 (en) 2000-01-31
CN1231176A (zh) 1999-10-13
EA199900124A3 (ru) 1999-12-29
BR9900653A (pt) 2000-10-17
HUP9900386A2 (hu) 1999-11-29
BG103180A (bg) 1999-09-30
OA10976A (en) 2001-11-05
AR017723A1 (es) 2001-09-12
AP9901464A0 (en) 1999-03-31
AU1732999A (en) 1999-09-02
CA2262252C (fr) 2006-01-10
ID23218A (id) 2000-03-30
EA199900124A2 (ru) 1999-08-26
MA26608A1 (fr) 2004-12-20
NO990722D0 (no) 1999-02-16
IS4975A (is) 1999-08-18
PA8467401A1 (es) 2000-09-29
GT199900015A (es) 2000-07-26
HRP990054A2 (en) 2000-02-29
PL331507A1 (en) 1999-08-30
HUP9900386A3 (en) 1999-12-28
NO990722L (no) 1999-08-18
SG81261A1 (en) 2001-06-19
EP0951906A1 (fr) 1999-10-27

Similar Documents

Publication Publication Date Title
ZA991220B (en) Method of treating heart failure.
EP1180040A4 (fr) Procedes de traitement de l'insuffisance cardiaque globale
AU2001249881A1 (en) Method of treating the heart
ZA997371B (en) Method of treating nitrate-induced tolerance.
ZA200108446B (en) Novel method of treatment.
ZA986363B (en) Novel method of treatment.
ZA985237B (en) Novel method of treatment.
HK1036019A1 (en) Treatment of cardiac hypertrophy.
ZA986364B (en) Novel method of treatment.
ZA974421B (en) Method of improving skin condition.
ZA986365B (en) Novel method of treatment.
PL341667A1 (en) Method of treating cooped
ZA987419B (en) Method for treating heart failure.
ZA977867B (en) Method of treatment.
GB9714841D0 (en) Treatment method
ZA200007396B (en) Method of treatment.
HK1039565A1 (en) Method of treating endotoxemia.
ZA975264B (en) Method for treating congestive heart failure.
AP2005003432A0 (en) Novel method of treatment.
ZA966970B (en) Water treatment method.
ZA972298B (en) Water treatment method.
HU9903735D0 (en) Method for treating congestive heart failure
ZA985238B (en) Novel method of treatment.
ZA985235B (en) Novel method of treatment.
ZA985236B (en) Novel method of treatment.